FDA Unveils 9 Drugs to Receive Expedited Reviews Under National Priority Voucher Program

‘We must modernize the review process and try new approaches to meet the needs of the American people,’ FDA Commissioner Dr. Marty Makary said.

Food and Drug Administration headquarters in White Oak, Maryland, on Aug. 29, 2020. Andrew Kelly/Reuters

The Food and Drug Administration (FDA) on Oct. 16 announced the first batch of drugs that will receive expedited reviews under the Commissioner’s National Priority Voucher (CNPV) pilot program.

“Voucher recipients will receive a decision within 1–2 months following filing of a complete application for a drug or biologic,” the FDA said, far outpacing the previous timelines.